FORT LAUDERDALE, Fla. — On this Healio Video Perspective from the Retina World Congress, Richard Small, CEO of Neurotech Prescribed drugs, gives an replace on Encelto for macular telangiectasia sort 2.
Forward of the encapsulated cell remedy’s June launch following its FDA approval earlier this yr, the corporate is educating retina specialists in addition to the broader eye care neighborhood on macular telangiectasia and Encelto (revakinagene taroretcel-lwey).
“We are literally getting ready to launch the product subsequent month,” Small mentioned.
Printed by:
